Search the Newsreel

Praxis Precision Medicines Inc (PRAX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Praxis Precision Medicines Inc.'s (PRAX) shareholder structure, detailing major shareholders, institutional holdings, and related ETF investments. Key shareholders include Janus Henderson Investors and Perceptive Advisors LLC, with significant institutional ownership changes over recent quarters. The data covers shareholder …

Praxis Precision Medicines Inc (PRAX) Institutional Confidence

Praxis Precision Medicines Inc (PRAX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional ownership stands at 114.11%, an increase of 24.71% quarter-over-quarter, with Steven Cohen being the largest individual institutional shareholder. Major institutional holders …

Orbimed Advisors LLC Raises Position in Praxis Precision Medicines, Inc. $PRAX

Orbimed Advisors LLC significantly increased its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) by 82.5% in the first quarter, now holding 172,500 shares valued at $55.6 million. The company reported a smaller-than-expected quarterly loss of $3.20 per share, surpassing analyst projections of a $3.58 …

SummitTX Capital L.P. Sells 4,791 Shares of Praxis Precision Medicines, Inc. $PRAX

SummitTX Capital L.P. decreased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 11.5% in the first quarter, selling 4,791 shares and retaining 36,838 shares valued at $11.9 million. Despite this, institutional investors and hedge funds own 67.84% of the company, with notable increases from …

Praxis Home Retail accepts resignation of Anou Singhvi as independent director

Praxis Precision Medicines Inc (PRAX) Balance Sheet - Tradingkey.com

This article from TradingKey.com provides a detailed balance sheet analysis for Praxis Precision Medicines Inc (PRAX), including quarterly and annual financial statements. It covers key metrics such as cash and short-term investments, total assets, liabilities, and shareholders' equity. The data allows investors to evaluate …

TradingKey

This page provides the quarterly and annual income statement for Praxis Precision Medicines Inc. (PRAX), detailing financial performance metrics such as total revenue, operating expenses, operating profit, net non-operating interest income, income before tax, and net income. It also includes frequently asked questions about …

Swiss National Bank Acquires 6,200 Shares of Praxis Precision Medicines, Inc. $PRAX

The Swiss National Bank increased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 15.3% in the first quarter, purchasing an additional 6,200 shares to bring its total holding to 46,700 shares valued at approximately $15 million. This move comes as other institutional investors have …

Allspring Global Investments Holdings LLC Grows Stake in Praxis Precision Medicines, Inc. $PRAX

Allspring Global Investments Holdings LLC significantly increased its stake in Praxis Precision Medicines, Inc. ($PRAX) by 392.8% in the first quarter of 2026, bringing their total holdings to 8,536 shares valued at $2,725,000. Other institutional investors also adjusted their positions in the company. Analysts …

Praxis Precision Medicines, Inc. Revenue Breakdown – NASDAQ:PRAX

PRAX|Praxis Precision Medicines Inc|Price:325.300|Chg%:+2.900

Praxis Precision Medicines Inc (PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system disorders, with its stock currently trading at $325.30. The company has strong fundamentals and high growth potential, evidenced by high institutional ownership and multiple "Buy" ratings from analysts with …

Understanding the Setup: (PRAX) and Scalable Risk

This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting divergent sentiment across different time horizons and suggesting choppy market conditions. It identifies an exceptional 85.2:1 risk-reward setup targeting a 24.6% gain against a 0.3% risk. The analysis provides specific trading strategies (Position, Momentum …

Praxis Precision Medicines (PRAX) Bank of America Global Healthcare Conference 2026 summary

Praxis Precision Medicines presented at the Bank of America Global Healthcare Conference 2026, outlining its strategy to manage a royalty portfolio of over 100 assets, with a focus on late-stage clinical and commercial assets. The company aims for 20% annual growth from its commercial …

PRAX stock trades around recent lows as Praxis Precision Medicines updates pipeline and cash runway

Praxis Precision Medicines Inc. (PRAX) is a clinical-stage neuroscience company whose stock is trading near recent lows due to ongoing clinical and financing risks. The company reported a substantial operating loss and a cash runway into early 2026 based on its 2024 financials, with …

Praxis Precision Medicines (PRAX) Could Be 49% Undervalued As Patch Deal Expands Ulixacaltamide Reach

Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?

Praxis Precision Medicines' collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide and the FDA's three-month extension for relutrigine's NDA review are significant developments for the company. These events could positively influence the perception of Praxis's pipeline durability and reach, particularly for …

Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree

Is FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)?

Praxis maps out two investor events in May, starting with Q1 results

Is Praxis Precision Medicines (PRAX) Pricing In Its 10x One Year Surge?

Praxis Precision Medicines Q4 Earnings Call Highlights

Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide